Article thumbnail

Clinical significance of HIV-1 coreceptor usage

By Hanneke Schuitemaker, Angélique B van 't Wout and Paolo Lusso

Abstract

The identification of phenotypically distinct HIV-1 variants with different prevalence during the progression of the disease has been one of the earliest discoveries in HIV-1 biology, but its relevance to AIDS pathogenesis remains only partially understood. The physiological basis for the phenotypic variability of HIV-1 was elucidated with the discovery of distinct coreceptors employed by the virus to infect susceptible cells. The role of the viral phenotype in the variable clinical course and treatment outcome of HIV-1 infection has been extensively investigated over the past two decades. In this review, we summarize the major findings on the clinical significance of the HIV-1 coreceptor usage

Topics: Review
Publisher: BioMed Central
OAI identifier: oai:pubmedcentral.nih.gov:3105505
Provided by: PubMed Central

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.

Suggested articles

Citations

  1. (1998). A conserved HIV gp120 glycoprotein structure involved in chemokine receptor binding. Science
  2. (2003). A new perspective on V3 phenotype prediction. AIDS Res Hum Retroviruses
  3. (2006). A reliable phenotype predictor for human immunodeficiency virus type 1 subtype C based on envelope V3 sequences.
  4. (2006). A: Primary CCR5 only using HIV-1 isolates does not accurately represent the in vivo replicating quasi-species. Virology
  5. (1998). AA: Gastrointestinal tract as a major site of CD4+ T cell depletion and viral replication in SIV infection. Science
  6. (2006). al: Genetic and functional analysis of R5X4 human immunodeficiency virus type 1 envelope glycoproteins derived from two individuals homozygous for the CCR5delta32 allele.
  7. (2008). al: Identification and characterization of transmitted and early founder virus envelopes in primary HIV-1 infection.
  8. (2008). al: Maraviroc for previously treated patients with R5 HIV-1 infection.
  9. (2010). al: Population-based sequencing of the V3-loop is comparable to the enhanced sensitivity Trofile assay in predicting virologic response to maraviroc of treatment-naïve patients in the MERIT trial.
  10. (2009). al: Spatial phylodynamics of HIV-1 epidemic emergence in east Africa. Aids
  11. (1994). al: Syncytiuminducing and non- syncytium-inducing capacity of human immunodeficiency virus type 1 subtypes other than B: phenotypic and genotypic characteristics. WHO Network for HIV Isolation and Characterization. AIDS Res Hum Retroviruses
  12. (2010). al: Wide variation in the multiplicity of HIV-1 infection among injection drug users.
  13. (2009). Angarano G: Co-receptor switch during HAART is independent of virological success.
  14. (1997). Appearance of autologous neutralizing antibody correlates with reduction in virus load and phenotype switch during primary infection with human immunodeficiency virus type 1. J Infect Dis
  15. (2005). Assessing chemokine coreceptor usage in HIV. Curr Opin Infect Dis
  16. (1998). Beretta A: HIV-1-resistance phenotype conferred by combination of two separate inherited mutations of CCR5 gene. Lancet
  17. (2005). BG: Epidemiology and predictive factors for chemokine receptor use in HIV-1 infection.
  18. (1993). Biological properties of HIV isolates in primary HIV infection: consequences for the subsequent course of infection. Aids
  19. (1994). Bozzette SA: The impact of the syncytium-inducing phenotype of human immunodeficiency virus on disease progression.
  20. (2005). Burastero SE: Cryptic nature of a conserved, CD4-inducible V3 loop neutralization epitope in the native envelope glycoprotein oligomer of CCR5-restricted, but not CXCR4-using, primary human immunodeficiency virus type 1 strains.
  21. (2007). Calvez V: HIV-1 X4/R5 co-receptor in viral reservoir during suppressive HAART. Aids
  22. (2000). Camerini D: Pathogenesis of primary R5 human immunodeficiency virus type 1 clones in SCID-hu mice.
  23. (1999). CC chemokine receptor 5 cell-surface expression in relation to CC chemokine receptor 5 genotype and the clinical course of HIV-1 infection.
  24. (2008). Chemokine (C-C motif) receptor 5-using envelopes predominate in dual/ mixed-tropic HIV from the plasma of drug-naive individuals. Aids
  25. (1998). Cheng-Mayer C: Mucosal transmission of pathogenic CXCR4-utilizing SHIVSF33A variants in rhesus macaques. Virology
  26. (2003). ChengMayer C: CD8+ T cell-mediated CXC chemokine receptor 4-simian/ human immunodeficiency virus suppression in dually infected rhesus macaques.
  27. (2007). CJ: Development and characterization of a novel single-cycle recombinant-virus assay to determine human immunodeficiency virus type 1 coreceptor tropism. Antimicrob Agents Chemother
  28. (2009). Collman RG: Heterosexual transmission of human immunodeficiency virus type 1 subtype C: Macrophage tropism, alternative coreceptor use, and the molecular anatomy of CCR5 utilization.
  29. (1999). Collman RG: Role of CXCR4 in cell-cell fusion and infection of monocytederived macrophages by primary human immunodeficiency virus type 1 (HIV-1) strains: two distinct mechanisms of HIV-1 dual tropism.
  30. (1997). CR: The HIV coreceptors CXCR4 and CCR5 are differentially expressed and regulated on human T lymphocytes.
  31. (1993). DD: Genotypic and phenotypic characterization of HIV-1 patients with primary infection. Science
  32. (1993). DD: Increased viral burden and cytopathicity correlate temporally with CD4+ T-lymphocyte decline and clinical progression in human immunodeficiency virus type 1-infected individuals.
  33. (2000). de Roda Husman AM, Schuitemaker H: Differential coreceptor expression allows for independent evolution of non-syncytium-inducing and syncytiuminducing HIV-1.
  34. (2006). DE: Human immunodeficiency virus type 1 coreceptor switching: V1/V2 gain-offitness mutations compensate for V3 loss-of-fitness mutations.
  35. (1999). Delaporte E: Evidence for differences in MT2 cell tropism according to genetic subtypes of HIV-1: syncytium-inducing variants seem rare among subtype C HIV-1 viruses. J Acquir Immune Defic Syndr Hum Retrovirol
  36. (1998). Differences in chemokine coreceptor usage between genetic subtypes of HIV-1. Virology
  37. (2006). Different rates of disease progression of HIV type 1 infection in Tanzania based on infecting subtype. Clin Infect Dis
  38. (2002). Diversity considerations in HIV-1 vaccine selection. Science
  39. (1998). Doms RW: HIV type I envelope determinants for use of the CCR2b, CCR3, STRL33, and APJ coreceptors.
  40. (2006). E: Emergence of CXCR4-using human immunodeficiency virus type 1 (HIV-1) variants in a minority of HIV-1-infected patients following treatment with the CCR5 antagonist maraviroc is from a pretreatment CXCR4-using virus reservoir.
  41. (1996). EA: HIV-1 entry cofactor: functional cDNA cloning of a seven-transmembrane, G protein-coupled receptor. Science
  42. (1998). Efficient inhibition of both syncytium-inducing and non-syncytium-inducing wild-type HIV-1 by lamivudine in vivo. Aids
  43. (1999). Emerging cytopathic and antigenic simian immunodeficiency virus variants influence AIDS progression. Nat Med
  44. (1997). et al: Association between CCR5 genotype and the clinical course of HIV-1 infection. Ann Intern Med
  45. (2009). et al: Characterization of human immunodeficiency virus type 1 populations containing CXCR4-using variants from recently infected individuals. AIDS Res Hum Retroviruses
  46. (1999). et al: Characterization of V3 sequence heterogeneity in subtype C human immunodeficiency virus type 1 isolates from Malawi: underrepresentation of X4 variants.
  47. (1999). et al: Consistent viral evolutionary changes associated with the progression of human immunodeficiency virus type 1 infection.
  48. (2009). et al: Contribution of Schuitemaker et al.
  49. (2007). et al: Coreceptor tropism in human immunodeficiency virus type 1 subtype D: high prevalence of CXCR4 tropism and heterogeneous composition of viral populations.
  50. (2008). et al: Deciphering human immunodeficiency virus type 1 transmission and early envelope diversification by single-genome amplification and sequencing.
  51. (2001). et al: Effects of CCR5-Delta32, CCR2-64I, and SDF-1 3’A alleles on HIV-1 disease progression: An international meta-analysis of individual-patient data.
  52. (2009). et al: Genetic identity, biological phenotype, and evolutionary pathways of transmitted/founder viruses in acute and early HIV-1 infection.
  53. (2007). et al: HIV type 1 chemokine coreceptor use among antiretroviral- experienced patients screened for a clinical trial of a CCR5 inhibitor: AIDS Clinical Trial Group A5211. Clin Infect Dis
  54. (2008). et al: HIV-1 envelope protein binds to and signals through integrin alpha4beta7, the gut mucosal homing receptor for peripheral T cells. Nat Immunol
  55. (1996). et al: Identification of a major co-receptor for primary isolates of HIV-1. Nature
  56. (1997). et al: In vivo evolution of HIV-1 co-receptor usage and sensitivity to chemokine-mediated suppression. Nat Med
  57. (2005). et al: Infection with multidrug resistant, dual-tropic HIV-1 and rapid progression to AIDS: a case report. Lancet
  58. (2009). et al: Inflammatory genital infections mitigate a severe genetic bottleneck in heterosexual transmission of subtype A and C HIV-1. PLoS Pathog
  59. (2006). et al: Prevalence of CXCR4 tropism among antiretroviral-treated HIV-1-infected patients with detectable viremia.
  60. (2009). et al: Quantitating the multiplicity of infection with human immunodeficiency virus type 1 subtype C reveals a non-poisson distribution of transmitted variants.
  61. (2009). et al: Response to vicriviroc in treatment-experienced subjects, as determined by an enhancedsensitivity coreceptor tropism assay: reanalysis of AIDS clinical trials group A5211. J Infect Dis
  62. (1988). et al: Risk of human immunodeficiency virus (HIV- 1) infection among laboratory workers. Science
  63. (1997). et al: Selective inhibition of syncytium- inducing and nonsyncytium-inducing HIV-1 variants in individuals receiving didanosine or zidovudine, respectively.
  64. (2008). et al: Subgroup analyses of maraviroc in previously treated R5 HIV-1 infection.
  65. (1995). et al: Syncytiuminducing (SI) phenotype suppression at seroconversion after intramuscular inoculation of a non-syncytium- inducing/SI phenotypically mixed human immunodeficiency virus population.
  66. (2003). Evolution of R5 and X4 human immunodeficiency virus type 1 gag sequences in vivo: evidence for recombination. Virology
  67. (1998). Evolution of syncytium-inducing and non-syncytium-inducing biological virus clones in relation to replication kinetics during the course of human immunodeficiency virus type 1 infection.
  68. (1992). Evolution of the V3 envelope domain in proviral sequences and isolates of human immunodeficiency virus type 1 during transition of the viral biological phenotype.
  69. (1999). Fauci AS: Both memory and CD45RA +/CD62L+ naive CD4(+) T cells are infected in human immunodeficiency virus type 1-infected individuals.
  70. (2004). Fenyo EM: Coevolution of RANTES sensitivity and mode of CCR5 receptor use by human immunodeficiency virus type 1 of the R5 phenotype.
  71. (2003). Fenyo EM: HIV biological variability unveiled: frequent isolations and chimeric receptors reveal unprecedented variation of coreceptor use. Aids
  72. (1999). Fenyo EM: Phenotypic characteristics of human immunodeficiency virus type 1 subtype C isolates of Ethiopian AIDS patients. AIDS Res Hum Retroviruses
  73. (1986). Fenyo EM: Replicative capacity of human immunodeficiency virus from patients with varying severity of HIV infection. Lancet
  74. (2008). Fogel GB: Prediction of R5, X4, and R5X4 HIV-1 coreceptor usage with evolved neural networks.
  75. (1996). Forceille C, et al: Resistance to HIV-1 infection in caucasian individuals bearing mutant alleles of the CCR-5 chemokine receptor gene. Nature
  76. (2010). Frequent CXCR4 tropism of HIV-1 subtype A and CRF02_AG during late-stage disease–indication of an evolving epidemic in West Africa. Retrovirology
  77. (2007). Frequent intrapatient recombination between human immunodeficiency virus type 1 R5 and X4 envelopes: implications for coreceptor switch.
  78. (2007). FS: Structural descriptors of gp120 V3 loop for the prediction of HIV-1 coreceptor usage. PLoS Comput Biol
  79. (2003). Genetic and biological properties of HIV type 1 isolates prevalent in villagers of the Cameroon equatorial rain forests and grass fields: further evidence of broad HIV type 1 genetic diversity. AIDS Res Hum Retroviruses
  80. (2002). Genotypic and phenotypic analysis of HIV type 1 primary isolates from western Cameroon. AIDS Res Hum Retroviruses
  81. (2006). Global and regional distribution of HIV- 1 genetic subtypes and recombinants in 2004. Aids
  82. (2003). High frequency of syncytium-inducing and CXCR4-tropic viruses among human immunodeficiency virus type 1 subtype Cinfected patients receiving antiretroviral treatment.
  83. (2006). HIV and the chemokine system: 10 years later. Embo J
  84. (2000). HIV type 1 envelope subtype C sequences from recent seroconverters in Zimbabwe. AIDS Res Hum Retroviruses
  85. (2002). HIV type 1 variants transmitted to women in Kenya require the CCR5 coreceptor for entry, regardless of the genetic complexity of the infecting virus. AIDS Res Hum Retroviruses
  86. (2008). HIV-1 coreceptor usage prediction without multiple alignments: an application of string kernels. Retrovirology
  87. (2007). HIV-1 subtype D infection is associated with faster disease progression than subtype A in spite of similar plasma HIV-1 loads. J Infect Dis
  88. (2000). Hovenkamp E, Schuitemaker H: In vivo HIV-1 infection of CD45RA(+)CD4(+) T cells is established primarily by syncytium- inducing variants and correlates with the rate of CD4(+) T cell decline. Proc Natl Acad Sci USA
  89. (1997). HW: The role of CCR5 and CCR2 polymorphisms in HIV-1 transmission and disease progression. Nat Med
  90. (1998). Identification of determinants on a dualtropic human immunodeficiency virus type 1 envelope glycoprotein that confer usage of CXCR4.
  91. (1991). Identification of human immunodeficiency virus envelope gene sequences influencing viral entry into CD4-positive HeLa cells, T-leukemia cells, and macrophages.
  92. Impact of HIV-1 viral subtype on disease progression and response to antiretroviral therapy.
  93. (2003). Improved coreceptor usage prediction and genotypic monitoring of R5-to-X4 transition by motif analysis of human immunodeficiency virus type 1 env V3 loop sequences.
  94. (2001). Improved success of phenotype prediction of the human immunodeficiency virus type 1 from envelope variable loop 3 sequence using neural networks. Virology
  95. (2008). In vitro characterization of multidrug-resistant HIV-1 isolates from a recently infected patient associated with dual tropism and rapid disease progression. J Acquir Immune Defic Syndr
  96. (2007). Increased neutralization sensitivity of recently emerged CXCR4-using human immunodeficiency virus type 1 strains compared to coexisting CCR5-using variants from the same patient.
  97. (1990). IS: HIV-1 tropism for mononuclear phagocytes can be determined by regions of gp120 outside the CD4-binding domain. Nature
  98. Izopet J: CXCR4-using viruses in plasma and peripheral blood mononuclear cells during primary HIV-1 infection and impact on disease progression.
  99. (2007). JA: Relation between chemokine receptor use, disease stage, and HIV-1 subtypes A and D: results from a rural Ugandan cohort. J Acquir Immune Defic Syndr
  100. (1998). JM: CXCR4 and CCR5 expression delineates targets for HIV-1 disruption of T cell differentiation.
  101. (1998). JP: Use of coreceptors other than CCR5 by nonsyncytium-inducing adult and pediatric isolates of human immunodeficiency virus type 1 is rare in vitro.
  102. (2010). Kozlov AP: A substantial transmission bottleneck among newly and recently HIV-1-infected injection drug users in St Petersburg,
  103. (2006). L: Genetic characteristics of the V3 region associated with CXCR4 usage in HIV-1 subtype C isolates. Virology
  104. (2010). Low frequency of CXCR4-using viruses in patients at the time of primary HIV-1 non-B infection.
  105. (1995). Lusso P: Identification of RANTES, MIP-1 alpha, and MIP-1 beta as the major HIVsuppressive factors produced by CD8+ T cells. Science
  106. (2003). Mammano F: Impact of antiretroviral treatment on the tropism of HIV-1 plasma virus populations. Aids
  107. (2008). Marck E, et al: Direct evidence of extensive diversity of HIV-1 in Kinshasa by 1960. Nature
  108. (1992). Minimal requirements for the human immunodeficiency virus type 1 V3 domain to support the syncytium- inducing phenotype: analysis by single amino acid substitution.
  109. (2009). ML: High frequency of X4/DM-tropic viruses
  110. (1994). MT-2 cell tropism of human immunodeficiency virus type 1 isolates as a marker for response to treatment and development of drug resistance.
  111. (2006). N: HIV-1 coreceptor use in triple-class treatment-experienced patients: baseline prevalence, correlates, and relationship to enfuvirtide response.
  112. (1997). NR: Change in coreceptor use correlates with disease progression in HIV-1–infected individuals.
  113. (1996). NR: Homozygous defect in HIV-1 coreceptor accounts for resistance of some multiply-exposed individuals to HIV-1 infection. Cell
  114. (2002). of 17type 1-infected and uninfected wives. AIDS Res Hum Retroviruses
  115. (2000). Oligomeric modeling and electrostatic analysis of the gp120 envelope glycoprotein of human immunodeficiency virus.
  116. (2008). Papathanasopoulos MA: Emergence of X4 usage among HIV-1 subtype C: evidence for an evolving epidemic in South Africa. Aids
  117. (2007). Perros M: Reduced maximal inhibition in phenotypic susceptibility assays indicates that viral strains resistant to the CCR5 antagonist maraviroc utilize inhibitor- bound receptor for entry.
  118. (2008). Petropoulos CJ: Coreceptor tropism can be influenced by amino acid substitutions in the gp41 transmembrane subunit of human immunodeficiency virus type 1 envelope protein.
  119. (2009). Petropoulos CJ: Vertical transmission of X4-tropic and dual-tropic HIV-1 in five Ugandan mother-infant pairs. Aids
  120. (1995). Phenotypic and genotypic characteristics of human immunodeficiency virus type 1 from patients with AIDS in northern Thailand.
  121. (2010). Poveda E: Dynamics of HIV tropism under suppressive antiretroviral therapy: implications for tropism testing in subjects with undetectable viraemia.
  122. (2008). PR: CD4-dependent characteristics of coreceptor use and HIV type 1 V3 sequence in a large population of therapy-naive individuals. AIDS Res Hum Retroviruses
  123. (2004). PR: Clinical and immunological impact of HIV envelope V3 sequence variation after starting initial triple antiretroviral therapy. Aids
  124. (2007). PR: Current V3 genotyping algorithms are inadequate for predicting X4 co-receptor usage in clinical isolates. Aids
  125. PR: Large-scale application of deep sequencing using 454 technology to HIV tropism screening.
  126. (2005). PR: Molecular and clinical epidemiology of CXCR4-using HIV-1 in a large population of antiretroviral-naive individuals.
  127. (2007). PR: Predicting HIV coreceptor usage on the basis of genetic and clinical covariates. Antivir Ther
  128. (2001). Preferential suppression of CXCR4-specific strains of HIV-1 by antiviral therapy.
  129. (2009). Quantifying differences in the tempo of human immunodeficiency virus type 1 subtype evolution.
  130. (2005). R5 to X4 switch of the predominant HIV-1 population in cellular reservoirs during effective highly active antiretroviral therapy. J Acquir Immune Defic Syndr
  131. (1998). RA: A new classification for HIV-1. Nature
  132. (2001). RA: Sexual risk behaviour relates to the virological and immunological improvements during highly active antiretroviral therapy in HIV-1 infection. Aids
  133. (1996). Relation between changes in cellular load, evolution of viral phenotype, and the clonal composition of virus populations in the course of human immunodeficiency virus type 1 infection.
  134. (2004). Resino S, et al: Virological phenotype switches under salvage therapy with lopinavir-ritonavir in heavily pretreated HIV-1 vertically infected children. Aids
  135. (1999). Rinke de Wit TF: HIV-1 subtype C syncytiumand non-syncytium-inducing phenotypes and coreceptor usage among Ethiopian patients with AIDS. Aids
  136. (1997). S: HIV type 1 V3 variation dynamics in vivo: long-term persistence of non- syncytium-inducing genotypes and transient presence of syncytium-inducing genotypes during the course of progressive AIDS. AIDS Res Hum Retroviruses
  137. (2000). Sattentau QJ: Selective interactions of polyanions with basic surfaces on human immunodeficiency virus type 1 gp120. J Virol
  138. (2008). Scarlatti G: HIV-1 with multiple CCR5/CXCR4 chimeric receptor use is predictive of immunological failure in infected children. PLoS One
  139. (1999). Schneweis KE: Protection against parenteral HIV-1 infection by homozygous deletion in the C-C chemokine receptor 5 gene. Aids
  140. Schuitemaker H: Changes in cellular virus load and zidovudine resistance of syncytium- inducing and non-syncytiuminducing human immunodeficiency virus populations under zidovudine pressure: a clonal analysis. JI n f e c tD i s1996,
  141. (1999). Schuitemaker H: Conversion rate towards a syncytium- inducing (SI) phenotype during different stages of human immunodeficiency virus type 1 infection and prognostic value of SI phenotype for survival after AIDS diagnosis. J Infect Dis
  142. (2010). Schuitemaker H: Genetic composition of replication competent clonal HIV-1 variants isolated from peripheral blood mononuclear cells (PBMC),
  143. (2004). Schuitemaker H: In vivo evolution of X4 human immunodeficiency virus type 1 variants in the natural course of infection coincides with decreasing sensitivity to CXCR4 antagonists.
  144. (1994). Schuitemaker H: Macrophage-tropic variants initiate human immunodeficiency virus type 1 infection after sexual, parenteral, and vertical transmission.
  145. (1992). Schuitemaker H: Phenotype-associated sequence variation in the third variable domain of the human immunodeficiency virus type 1 gp120 molecule.
  146. (1993). Schuitemaker H: Relation of phenotype evolution of HIV-1 to envelope V2 configuration. Science
  147. (2005). Selection of human immunodeficiency virus type 1 R5 variants with augmented replicative capacity and reduced sensitivity to entry inhibitors during severe immunodeficiency.
  148. (2005). Sensitivity of primary R5 HTV-1 to inhibition by RANTES correlates with sensitivity to small-molecule R5 inhibitors. Antivir Ther
  149. (2006). Shattock R: Selective transmission of CCR5-utilizing HIV-1: the ‘gatekeeper’ problem resolved? Nat Rev Microbiol
  150. (1992). Small amino acid changes in the V3 hypervariable region of gp120 can affect the T-cell-line and macrophage tropism of human immunodeficiency virus type 1. Proc Natl Acad Sci U S A
  151. (2007). Soriano V: Prevalence of X4 tropic HIV-1 variants in patients with differences in disease stage and exposure to antiretroviral therapy.
  152. (2002). SP: HIV-1 infection in individuals with the CCR5-Delta32/Delta32 genotype: acquisition of syncytium-inducing virus at seroconversion. J Acquir Immune Defic Syndr
  153. (2010). Stable coreceptor usage of Schuitemaker et al.
  154. (1998). Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody. Nature
  155. (2009). Stuyver L: CXCR4-using HIV type 1 variants are more commonly found in peripheral blood mononuclear cell DNA than in plasma RNA. J Acquir Immune Defic Syndr
  156. (1992). Tersmette M: Biological phenotype of human immunodeficiency virus type 1 clones at different stages of infection: progression of disease is associated with a shift from monocytotropic to T-cell-tropic virus population.
  157. (1992). Tersmette M: HIV-1 biological phenotype in long-term infected individuals evaluated with an MT-2 cocultivation assay. Aids
  158. (1993). Tersmette M: Prognostic value of HIV-1 syncytiuminducing phenotype for rate of CD4+ cell depletion and progression to AIDS. Ann Intern Med
  159. (1998). The ability of HIV type 1 to use CCR-3 as a coreceptor is controlled by envelope V1/V2 sequences acting in conjunction with a CCR-5 tropic V3 loop.
  160. (2008). The impact of HIV tropism on decreases in CD4 cell count, clinical progression, and subsequent response to a first antiretroviral therapy regimen. Clin Infect Dis
  161. (2008). V: Impact of antiretroviral therapy on viral tropism in HIV-infected patients followed longitudinally for over 5 years.
  162. (2009). van ‘t Wout AB: Comparison of human immunodeficiency virus type 1 tropism profiles in clinical samples by the Trofile and MT-2 assays. Antimicrob Agents Chemother
  163. (2002). Variability in the human immunodeficiency virus type 1 gp120 Env protein linked to phenotype- associated changes in the V3 loop.
  164. (1993). Viral phenotype and T cell reactivity in human immunodeficiency virus type 1-infected asymptomatic men treated with zidovudine.
  165. (2000). YJ: Recovery of replication-competent virus from CD4 T cell reservoirs and change in coreceptor use in human immunodeficiency virus type 1- infected children responding to highly active antiretroviral therapy. J Infect Dis
  166. (2007). Zhang C: Improved prediction of coreceptor usage and phenotype of HIV-1 based on combined features of V3 loop sequence using random forest.
  167. (1998). Zolla-Pazner S: Neutralization profiles of primary human immunodeficiency virus type 1 isolates in the context of coreceptor usage.